CCRM Australia has partnered with local and international venture capital firms to launch the International Regenerative Medicine SuperPitch. The SuperPitch offers expertise and investment funding for translation and commercialisation of Australian regenerative medicine and related projects. CCRM Australia’s SuperPitch IV extends to CCRM Hubs in Canada, the Netherlands and the Nordic States.

Regenerative medicine includes technologies and therapies that regenerate or replace injured, diseased, or defective cells, tissues, or organs to restore or establish function and structure. Submissions may relate to cell therapies, gene therapies, combination therapies, gene editing tools, enabling technologies such as vector production, automated analytical essays, biosensors, novel media, and other projects related to regenerative medicine in a wide range of therapeutic areas.

The International Regenerative Medicine SuperPitch IV provides an opportunity for companies and researchers to showcase their technologies or ideas. Expert feedback, commercialisation support from CCRM Australia and, for suitable projects, further development funding will be made available. The participation of partners with expertise in various specialties and lifecycle stages empowers the SuperPitch to streamline progress from proof of concept through to clinical trials.

Shortlisted applicants will be invited to provide a forty-minute presentation, which must include objective data on their technologies to a panel of regenerative medicine, venture capital and commercialisation experts from the consortia. The International Regenerative Medicine SuperPitch IV will be held online on 18th of November 2021. The video conferencing application Zoom will be used for all participants.

Key Dates:

Application via expression of interest close 5pm AEST 19 October 2021

Shortlisted applicants will be informed during the week commencing 25 October 2021

SuperPitch event: 18 November 2021


Expression of interest form

CCRM Australia International Regenerative Medicine SuperPitch IV Flyer

For more information and to apply

Contact Dr Chih Wei Teng, Chief Operating Officer at

SuperPitch IV Panel Participants include representatives from the following organisations

CCRM Ventures, Bridge Bio, TDM Growth Partners, LifeSci Advisors, Morningside, Starfish Ventures, AllosteRx Capital and Eureka Technology Innovation and Investment

This venture has received funding through the MTPConnect Project Fund Program – a dollar-to-dollar matched program investing in big, bold ideas to improve the productivity, competitiveness and innovative capacity of Australia’s medical technology, biotechnology and pharmaceutical sector. MTPConnect is supported by the Australian Government Industry Growth Centres Initiative – learn more at